Which characteristics are associated with changes in medication status for lower urinary tract symptoms among patients with prostate cancer receiving external beam radiotherapy?
Authors:
- Yuki KyodaYKYuki Kyoda
- Kohei HashimotoKHKohei Hashimoto
- Atsushi TakahashiATAtsushi Takahashi
- Takeshi MaehanaTMTakeshi Maehana
- Kimihito TachikawaKTKimihito Tachikawa
- Takashi MuranakaTMTakashi Muranaka
- Shuichi KatoSKShuichi Kato
- Tomoyo KurisuTKTomoyo Kurisu
- Fumimasa FukutaFFFumimasa Fukuta
- Takahiro KirisawaTKTakahiro Kirisawa
- Manabu OkadaMOManabu Okada
- Ko KobayashiKKKo Kobayashi
Open Access
- 27 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Current Urology
- Vol. 18 (2) , 122-127
Abstract
Background: We clarified the predictive factors for changes in the status of medications for lower urinary tract symptoms (LUTS) 2 years after local radiotherapy for nonmetastatic prostate cancer. Materials and methods: We retrospectively included patients who underwent local external radiotherapy for nonmetastatic prostate cancer in 8 institutions between April 2001 and March 2016. Patients were divided into the medication and no-medication group based on the use of drugs for LUTS before radiotherapy. We defined improvement of LUTS as when the patient did not require medication for LUTS at 24 months after radiotherapy in the medication group and as deterioration when medication was required in the no-medication group. Logistic regression analysis was used to evaluate predictive factors for changes in medication status. Results: Altogether, 505 patients were divided into a no-medication group (n = 352) and a medication group (n = 153). The number of patients with deterioration and improvement in LUTS was 49 (14%) and 36 (23%), respectively. In the multivariate analysis, the predictive variables for deterioration were the International Prostate Symptom Score (≥8; odds ratio [OR], 2.21; p = 0.014) and the biopsy Gleason score (≤3 + 4 = 7; OR, 2.430; p = 0.008) in the no-medication group, whereas those for improvement were age (p = 0.002), the quality of life score (p = 0.028), and a positive biopsy core rate (≥50%; OR, 2.530; p = 0.027) in the medication group. Conclusions: These predictive factors for changes in the status of medications for LUTS at 2 years after external radiotherapy may help determine the definitive therapy for nonmetastatic prostate cancer.Keywords
This publication has 22 references indexed in Scilit:
- The Primary Local Stage at Diagnosis Predicts Regional Symptoms Caused by Local Progression in Patients With Castration-resistant Prostate CancerUrology, 2015
- Detrusor Underactivity and the Underactive Bladder: A New Clinical Entity? A Review of Current Terminology, Definitions, Epidemiology, Aetiology, and DiagnosisEuropean Urology, 2014
- Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus BicalutamideClinical Oncology, 2013
- Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamideBJU International, 2012
- Natural history of lower urinary tract symptoms in Japanese men from a 15‐year longitudinal community‐based studyBJU International, 2012
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialThe Lancet, 2011
- Periacinar Retraction Clefting in Nonneoplastic and Neoplastic Prostatic Glands: Artifact or Molecular InvolvementPathology and Oncology Research, 2011
- Perspectives on overactive bladder in the elderly populationWorld Journal of Urology, 2009
- Quality of Life and Satisfaction with Outcome among Prostate-Cancer SurvivorsNew England Journal of Medicine, 2008
- Predictors for Chronic Urinary Toxicity After the Treatment of Prostate Cancer With Adaptive Three-Dimensional Conformal Radiotherapy: Dose–Volume Analysis of a Phase II Dose-Escalation StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007